AorticLab Triumphs Over Emboline in UPC Patent Litigation, Securing Patient Access

AorticLab's Significant Victory at the Unified Patent Court

In a landmark ruling, AorticLab S.r.l. has emerged victorious at the Unified Patent Court's (UPC) Local Division in Munich, effectively dismissing the patent infringement claims raised by Emboline, Inc. This decision allows AorticLab to continue providing its groundbreaking FLOWer™ embolic protection device to patients across Europe.

The UPC's ruling, delivered on January 13, 2026, stated that AorticLab's FLOWer™ device does not infringe upon Emboline’s European Patent EP2129425. The outcome is significant not only for AorticLab but also for patients undergoing interventional cardiology procedures, as it ensures continuous access to this innovative and essential medical technology.

The FLOWer™ device is recognized as the only full-body anti-embolic protection system available in Europe, offering a crucial safeguard during potentially high-risk heart procedures. AorticLab's commitment to enhancing embolic protection through advanced engineering practices has garnered a strong reputation in the medical community, contributing to improved patient outcomes.

Franco Osta, Chief Executive Officer of AorticLab, emphasized the importance of this ruling for the company’s growth strategies. “This decision provides us with the clarity required to accelerate our market growth plans, expanding not just within Europe but also targeting the United States where we have already initiated an IDE Clinical Trial,” Osta stated. The company aims to leverage this win to boost its operations in high-impact transcatheter procedures.

During the UPC proceedings, AorticLab was backed by a seasoned legal team that included notable attorneys such as Sabine Agé from HOYNG ROKH MONEGIER and André Roland from ANDRÉ ROLAND SA. Their expertise played a key role in navigating the complexities of patent law and effectively defending AorticLab’s innovations.

In further insights, Enrico Pasquino, Chief Technology Officer, highlighted the revolutionary aspects of the FLOWer™ system. “Our device represents a paradigm shift in cerebral protection, specifically engineered to mitigate the risk of stroke during intricate TAVI procedures,” he explained. This reflects AorticLab’s dedication to not only advance medical technology but also ensure patient safety in turbulent clinical environments.

The company's patent victory not only reinforces AorticLab’s growth trajectory but also instills confidence among stakeholders, including investors and clinical partners. Carlo Vanoli, Chairman of AorticLab, expressed his thoughts, stating, “This judgment confirms the strength and expansion of AorticLab's intellectual property and empowers us to continue our mission to deliver advanced, safe, and innovative medical devices for cardiac patients.”

Beyond the FLOWer™ system, AorticLab’s device portfolio includes a cutting-edge transcatheter ultrasound debridement system, showcasing their commitment to excellence in managing aortic valve diseases. The company’s efforts are directed towards creating devices that enhance procedural safety and improve overall patient health outcomes.

With the UPC’s verdict solidly behind them, AorticLab is set to focus on scaling its innovative solutions and fulfilling its mission of providing high-quality medical products that are pivotal in modern interventional cardiology. As patients and medical professionals alike will benefit from this ruling, it marks a significant chapter in AorticLab's journey towards advancing healthcare technology worldwide.